GlassScriptPhysician profile
Elizabeth Coulson
NPI 1487251930
$873.82
in general payments reported to CMS, 2019-2025
18 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $146 · 2024: $363 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $142.82 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $132.88 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Gilead Sciences, INC. | $110.08 | 2024-2025 | |
| Axsome Therapeutics, INC. | $86.64 | 2024-2025 | Auvelity |
| Indivior INC. | $65.90 | 2023-2025 | Perseris, Sublocade |
| Janssen Pharmaceuticals, INC | $54.66 | 2023-2024 | Spravato, Invega Sustenna |
| Alkermes, INC. | $38.13 | 2023-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $37.03 | 2025 | Cobenfy |
| Luye Pharma (USA) LTD. | $33.18 | 2025 | Erzofri Extended-Release |
| Neurocrine Biosciences, INC. | $25.34 | 2025 | |
| Viiv Healthcare Company | $24.09 | 2025 | Apretude |
| Lilly USA, LLC | $21.48 | 2025 | Mounjaro |
| Boston Scientific Corporation | $21.35 | 2024 | |
| Corium, LLC | $20.02 | 2024 | Azstarys |
| Pfizer INC. | $16.26 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $15.04 | 2024 | Xelstrym |
| Teva Pharmaceuticals USA, INC. | $15.02 | 2024 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.90 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Coulson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.